<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Neuropsychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Neuropsychiatry</journal-id>
<journal-id journal-id-type="publisher-id">MNP</journal-id>
<journal-title-group>
<journal-title>Molecular Neuropsychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2296-9209</issn>
<issn pub-type="epub">2296-9179</issn>
<publisher>
<publisher-name>S. Karger AG</publisher-name>
<publisher-loc>Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH-4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31768375</article-id>
<article-id pub-id-type="pmc">6873013</article-id>
<article-id pub-id-type="doi">10.1159/000501797</article-id>
<article-id pub-id-type="publisher-id">mnp-0005-0218</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Commentary</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Research Domain Criteria: Strengths, Weaknesses, and Potential Alternatives for Future Psychiatric Research</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ross</surname>
<given-names>Christopher A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Margolis</surname>
<given-names>Russell L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>a</sup>Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
<aff id="aff2"><sup>b</sup>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
<aff id="aff3"><sup>c</sup>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
<aff id="aff4"><sup>d</sup>Department of Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
<aff id="aff5"><sup>e</sup>Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
<author-notes>
<corresp id="cor1">*Dr. Christopher A. Ross, Johns Hopkins University School of Medicine, CMSC 8-121, 600 N. Wolfe Street, Baltimore, MD 21287 (USA), E-Mail <email>caross@jhu.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>13</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>8</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>5</volume>
<issue>4</issue>
<fpage>218</fpage>
<lpage>236</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="subscription-year">
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 by S. Karger AG, Basel</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<p>The Research Domain Criteria (RDoC) paradigm was launched 10 years ago as a superior approach for investigation of mental illness. RDoC conceptualizes normal human behavior, emotion, and cognition as dimensional, with mental illnesses as dimensional extremes. We suggest that RDoC may have value for understanding normal human psychology and some conditions plausibly construed as extremes of normal variation. By contrast, for the most serious of mental illnesses, including dementia, autism, schizophrenia, and bipolar disorder, we argue that RDoC is conceptually flawed. RDoC conflates variation along dimensional axes of normal function with quantitative measurements of disease phenotypes and with the occurrence of diseases in overlapping clusters or spectra. This moves away from the disease model of major mental illness. Further, RDoC imposes a top-down approach to research. We argue that progress in major mental illness research will be more rapid with a bottom-up approach, starting with the discovery of etiological factors, proceeding to investigation of pathogenic pathways, including use of cell and animal models, and leading to a refined nosology and novel, targeted treatments.</p>
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>Research Domain Criteria</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Bipolar disorder</kwd>
<kwd>Autism</kwd>
<kwd>Psychosis</kwd>
<kwd>Dimension</kwd>
<kwd>Category</kwd>
<kwd>Diagnosis</kwd>
<kwd>Nosology</kwd>
<kwd>Genetics</kwd>
<kwd>Gene-environment interaction</kwd>
<kwd>National Institute of Mental Health</kwd>
<kwd>Spectrum</kwd>
</kwd-group>
<counts>
<fig-count count="6"></fig-count>
<ref-count count="93"></ref-count>
<page-count count="18"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>